Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Lowers FY2026 Sales Guidance from $600.000M-$610.000M to $590.000M-$595.000M vs $604.782M Est
Benzinga Newsdesk 2 days ago
NewsGuidance
Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Lowers FY2026 sales outlook from $600.000 million-$610.000 million to $590.000 million-$595.000 million
Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Lowers FY2026 sales outlook from $600.000 million-$610.000 million to $590.000 million-$595.000 million vs $604.782 million estimate.